Hematology Advisor asked Prithviraj Bose, MD, to discuss the latest research on treatment options for CLL presented at the ASH 2018 Annual Meeting.
Minimal residual disease from peripheral blood, which is easier to obtain than bone marrow, was found to correlate with some clinical outcomes.
Patients receiving ponatinib in combination with other therapeutic agents appeared to achieve sustained responses and long-term remission.
The expanded approval was supported by data from the Phase 2 multicenter, single-arm CA180-372 study (NCT01460160) which included 78 pediatric patients with newly diagnosed B-cell precursor Ph+ ALL.
Two Mutations Prognostic of Survival in Acute Myeloid Leukemia Regardless of Hematopoietic Stem Cell Transplantation
Internal tandem duplications in FLT3 and mutations in CEBPA were independently prognostic of overall survival in patients with acute myeloid leukemia.
Results of a study on the influence of induction chemotherapy on transplant outcomes for patients with acute myeloid leukemia.
Measurable residual disease status can inform treatment for patients with ALL, but the optimal methods for assessment and interpretation are unclear.
Researchers evaluated the proportion of patients who had not experienced relapse at 6 months after initiation of azacitidine treatment.
The researchers reported more than 75% of patients achieved complete response after 1 cycle of the intensive chemotherapy regimen.
A combination of alvocidib, cytarabine, and mitoxantron was found to outperform other novel treatments for relapsed/refractory acute myeloid leukemia.
From May 1 2018 to July 31 2018, 5 cases of death associated with DS in patients taking Idhifa have been reported; in 2 of these cases, DS was listed as the only cause of death.
Researchers retrospectively analyzed data from 508 patients with chronic myeloid leukemia who had received bone marrow aspiration or core biopsy.
Inotuzumab Ozogamicin May Be Efficacious and Safe in Relapsed Pediatric Acute Lymphoblastic Leukemia
The efficacy of inotuzumab ozogamicin in pediatric patients is less understood than in adult patients.
For children with relapsed or refractory B-cell acute lymphoblastic leukemia, tisagenlecleucel was deemed cost-effective, yet long-term outcomes are still uncertain.
For patients in the chronic phase of chronic myeloid leukemia, nilotinib and dasatinib showed comparable efficacy as frontline single agents.
Investigators found that dosing of IgRT in CLL at target levels higher than conventional parameters may offer a therapeutic benefit.
Using a longitudinal parallel-process model, researchers evaluated the impact of physical activity on symptoms, physical activity, and cognitive function in children with ALL undergoing chemotherapy.
Researchers hypothesized that a combination bispecific mAb in B-cell malignancies could offer a treatment option superior to existing monospecific mAbs.